Masimo Corporation (NASDAQ:MASI) Receives $181.17 Consensus PT from Analysts

Shares of Masimo Corporation (NASDAQ:MASI) have received a consensus rating of “Reduce” from the nine research firms that are currently covering the company, Marketbeat.com reports. One equities research analyst has rated the stock with a sell recommendation and eight have given a hold recommendation to the company. The average twelve-month target price among brokerages that have updated their coverage on the stock in the last year is $181.1667.

MASI has been the subject of a number of recent research reports. BTIG Research cut Masimo from a “buy” rating to a “neutral” rating in a report on Wednesday, February 18th. Stifel Nicolaus set a $180.00 price objective on Masimo in a research note on Tuesday, February 17th. Wolfe Research downgraded shares of Masimo from a “strong-buy” rating to a “hold” rating in a research report on Thursday, February 19th. Raymond James Financial lowered shares of Masimo from an “outperform” rating to a “market perform” rating in a report on Friday, March 27th. Finally, Wells Fargo & Company raised shares of Masimo to a “hold” rating in a research note on Wednesday, March 18th.

Institutional Investors Weigh In On Masimo

Several institutional investors and hedge funds have recently made changes to their positions in MASI. MAI Capital Management boosted its holdings in Masimo by 176.7% in the second quarter. MAI Capital Management now owns 202 shares of the medical equipment provider’s stock valued at $34,000 after acquiring an additional 129 shares during the last quarter. Global Retirement Partners LLC bought a new stake in shares of Masimo in the 4th quarter valued at $27,000. Aster Capital Management DIFC Ltd acquired a new stake in shares of Masimo during the fourth quarter worth $28,000. Los Angeles Capital Management LLC bought a new position in Masimo during the fourth quarter worth $31,000. Finally, Rothschild Investment LLC boosted its position in Masimo by 12,950.0% during the fourth quarter. Rothschild Investment LLC now owns 261 shares of the medical equipment provider’s stock valued at $34,000 after acquiring an additional 259 shares during the last quarter. Institutional investors and hedge funds own 85.96% of the company’s stock.

Masimo Price Performance

MASI stock opened at $177.87 on Friday. The stock has a market cap of $9.55 billion, a price-to-earnings ratio of -16.88, a P/E/G ratio of 1.80 and a beta of 1.21. The company has a debt-to-equity ratio of 0.72, a current ratio of 2.49 and a quick ratio of 1.47. The company has a 50 day simple moving average of $161.34 and a 200 day simple moving average of $148.77. Masimo has a 1 year low of $125.94 and a 1 year high of $179.00.

Masimo Company Profile

Masimo (NASDAQ: MASI) is a global medical technology company specializing in noninvasive monitoring solutions. The company’s flagship technology, Masimo SET® (Signal Extraction Technology), enhances the accuracy of pulse oximetry in challenging clinical conditions. Beyond pulse oximetry, Masimo’s portfolio extends to brain function monitoring, regional oximetry, and acoustic respiration rate monitoring, serving critical, acute, and ambulatory care settings.

In addition to its core monitoring technologies, Masimo offers a range of patient cables, sensors, and connectivity platforms designed to integrate with hospital information systems and remote monitoring applications.